Important information

This website is for Institutional Investors in Taiwan only.

 

If you are an Individual Investor click here, if you are an Financial Intermediary click here. Should you be looking for information for another location, please click here.

 

By clicking, you acknowledge that you have fully understood and accepted the Legal and Regulatory Information.

ESG The future of health care: Medtech’s innovation hotspots

Belinda Gan Lily Ghebrai

16 December 2025

Chronic disease is on the rise and populations are ageing.

Innovative medical technology (medtech) that helps address some of the resulting challenges to health and well-being offers significant growth potential.

KEY TAKEAWAYS

  • Chronic diseases are among the leading causes of death worldwide, and their rising prevalence is driving massive spending in health care. Breakthroughs in medical technology are creating compelling long-term investment opportunities.
  • Diabetes is one of the chronic diseases on the rise. Medical devices to help monitor and manage the disease represent sizeable growth potential.
  • Radiology and cardiovascular devices are at the forefront of AI adoption, and cancer detection is poised for a technological revolution.
  • Novel consumer-facing medtech products, such as next-generation hearing aids, are a fast-changing area where we see new entrants driving disruption.

Taking the pulse on investment opportunities in medtech

Explore some of our investment team’s latest thinking on the products, and the health care and consumer firms to watch.

DOWNLOAD RESEARCH

Explore the latest research and insights in our environmental, social and governance (ESG) perspectives library

Explore now

Belinda Gan is an ESG investment director with 20 years of industry experience (as of 12/31/2024). She holds a bachelor's degree in commerce and a bachelor's degree in business systems from Monash University, Australia. She also holds the Chartered Financial Analyst® designation.

Lily Ghebrai is an ESG analyst at Capital Group covering biopharma, health care services and medtech. She has 10 years of investment industry experience and has been with Capital Group for one year (as of 12/31/2024). She holds a master's degree in public administration from The School of International and Public Affairs at Columbia University and a bachelor's degree from Middlebury College.

Your gateway to all things ESG at Capital Group

LEARN MORE
Past results are not predictive of results in future periods. It is not possible to invest directly in an index, which is unmanaged. The value of investments and income from them can go down as well as up and you may lose some or all of your initial investment. This information is not intended to provide investment, tax or other advice, or to be a solicitation to buy or sell any securities.
 
Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. All information is as at the date indicated unless otherwise stated. Some information may have been obtained from third parties, and as such the reliability of that information is not guaranteed.
 
Capital Group manages equity assets through three investment groups. These groups make investment and proxy voting decisions independently. Fixed income investment professionals provide fixed income research and investment management across the Capital organisation; however, for securities with equity characteristics, they act solely on behalf of one of the three equity investment groups.